GO
Loading...

Vertex Pharmaceuticals Inc

More

  • Futures Pare Gains on Earnings; GE, MCD Lower Friday, 19 Apr 2013 | 8:26 AM ET

    U.S. stock index futures trimmed some gains Friday, with major averages poised to post their worst weekly declines this year, as investors reacted to the latest wave of earnings reports.

  • Early Movers: GE, MDLZ, DELL & More Friday, 19 Apr 2013 | 7:35 AM ET

    Check out which companies are making headlines before the bell on Friday:

  • After-Hours Buzz: GOOG, IBM, MSFT & More Thursday, 18 Apr 2013 | 4:42 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • Final Trade: Your First Move for Friday, April 19 Thursday, 18 Apr 2013 | 1:39 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Cramer: 3 Stocks on the Speculative Side Tuesday, 2 Apr 2013 | 6:27 PM ET

    Cramer thinks any one of the following 3 stocks deserves a spot inside a properly diversified portfolio.

  • Generics Brought Down Common Drug Prices Tuesday, 5 Mar 2013 | 11:15 AM ET

    Spending on drugs to treat common diseases fell 1.5 percent among customers who receive prescription benefits through commercial insurers.

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • *3rd quarter net loss 27 cents a share. Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by fast-declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • UPDATE 2-Vertex posts loss as hepatitis drug sales fall Thursday, 1 Nov 2012 | 10:52 PM ET

    Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • *3rd quarter net loss 27 cents a share. Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by fast-declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • --Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.

  • --Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.

  • --Martha Stewart Living Omnimedia Inc rescheduled third-quarter results to Nov. 1 from Oct. 30. --Vertex Pharmaceuticals Inc rescheduled third-quarter 2012 earnings and conference call to after markets close on Nov. 1 from Oct. 29. --The McGraw-Hill Companies Inc rescheduled third-quarter earnings and conference call to Nov. 2 from Oct. 31.

  • Abbott Labs rises on hepatitis C drug data Monday, 15 Oct 2012 | 11:48 AM ET

    NEW YORK-- Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease. Abbott shares rose $2.77, or 4 percent, to close at $72.05 Monday.

  • Oct 11- Vertex Pharmaceuticals Inc:. *Data from phase 2 combination study of vx-809 and ivacaftor in people with. cystic fibrosis who have the most common genetic mutation presented.

  • Stocks to Watch: JNJ, LLY, EW & More Tuesday, 9 Oct 2012 | 8:08 AM ET

    Take a look at some of Tuesdays morning movers.

  • Oct 2- Vertex Pharmaceuticals Inc:. *Lazard raises Vertex Pharmaceuticals Inc price target to $75 from. Reuters Station users, click. 1568.

  • Bristol’s Hep C Drug Blowup May Benefit These Stocks Thursday, 2 Aug 2012 | 10:51 AM ET

    Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.

  • Stocks to Watch: BBY, HMA, THC & More Thursday, 28 Jun 2012 | 1:37 PM ET

    Take a look at some of Thursday's midday movers:

Most Popular Video

Tuesday, 15 Apr 2014 | 4:07 PM ET

"Yahoo's core business is still limping along," says Colin Gillis, BGC Financial, while providing instant reaction to Yahoo's quarterly numbers. "Shark Tank" investor Kevin O'Leary and "The Profit's" Marcus Lemonis weigh in.

Tuesday, 15 Apr 2014 | 11:31 PM ET

John Sculley, former Apple CEO and Managing Partner at Inflexionpoint, discusses his company's acquisitions in Singapore and India.

Tuesday, 15 Apr 2014 | 11:14 PM ET

Will Oswald, Global Head of FICC Research at Standard Chartered, says Beijing has the tools to guide its economy to a soft landing.